Share

Apeloa Pharmaceutical Co.,Ltd Stocks

CN¥ 17.1Last Updated 05.03.2026

Issuer Rating

6/7

Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 2.84B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 17.1
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Apeloa Pharmaceutical Co.,Ltd researches and develops, produces, and sells pharmaceutical products in China and internationally. It provides products in the cardio-cerebrovascular, anti-infection, anti-viral, anti-tumor, and other treatment areas. The company offers preparations, raw material intermediates, and veterinary drugs primarily under the Tianliwei, Beshin, Yosemade, Jutai, and other brands. It also provides contract research and development,...

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 000739.SZ is 19 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks